KeyBank, Others Finance BioClinica, CoreLab Merger
BioClinica announced that JLL Partners and Ampersand Capital Partners completed their acquisition of BioClinica and CoreLab Partners and have combined the two companies under the name BioClinica.
In connection with the transaction, KeyBank, CIT Finance and U.S. Bank acted as the lead arrangers and joint bookrunners for the $100 million of senior secured facilities. The facilities consist of a $75 million term loan facility and $25 million revolving facility, undrawn at close.
This merger brings together two authorities in medical imaging management for clinical trials and creates a new standard in imaging core lab services, cardiovascular safety monitoring and eClinical trial management solutions.
“The unification of BioClinica and CoreLab Partners will enhance the existing service quality and technological innovation supported by scientific and medical expertise that have long been hallmarks of these two companies,” said Mark Weinstein, who will lead the newly combined company as president and CEO. “This merger produces a stronger BioClinica that is better able to support pharmaceutical, biotechnology, and medical device development.”
Dan Agroskin, managing director of JLL Partners said, “JLL has spent a significant amount of time gaining an understanding of the pharmaceutical outsourcing sector and, as a result, we are pleased to have made these two acquisitions. This combination brings together two industry leading companies that we are confident will continue to deliver a strong service offering to their customers. We are excited by the growth potential of this newly formed platform, and we look forward to working with the talented management of BioClinica and CoreLab Partners as they continue to enhance their best-in-class capabilities.”
BioClinica is a global provider of integrated, technology-enhanced clinical trial management services.
JLL Partners is a New York-based private equity investment firm.
Ampersand Capital Partners, based in Boston, is a private equity firm that focuses on middle-market growth equity investments in the healthcare sector.